# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce prostate cancer and BPH
- describe limitations of PSA test
- highlight need for novel biomarkers

## SUMMARY OF THE INVENTION

- introduce new biomarkers for distinguishing BPH and PCa
- describe method for distinguishing BPH and PCa
- correlate biomarker levels to reference level
- provide report indicating PCa or BPH
- describe reference level
- specify biomarkers
- describe sample types
- describe methods for determining biomarker levels
- describe diagnosis in combination with PSA test
- introduce method for diagnosing PCa
- introduce method for monitoring PCa recurrence

## DETAILED DESCRIPTION OF THE INVENTION

- introduce problem of distinguishing BPH and PCa
- define prostate cancer and BPH
- discuss limitations of PSA screening
- motivate need for new biomarkers
- describe biomarkers for distinguishing BPH and PCa
- outline method for distinguishing BPH and PCa
- describe method for diagnosing prostate cancer
- describe method for monitoring prostate cancer recurrence
- discuss MUC3 as a biomarker
- discuss PGA3 as a biomarker
- discuss Î²2M as a biomarker
- discuss uromodulin as a biomarker
- discuss additional biomarkers
- conclude biomarkers for distinguishing BPH and PCa
- describe collagen alpha 1 chain precursor variant
- describe ankyrin repeat domain-containing protein 11
- describe pro-alpha 2(I) collagen
- describe sulfatase 2 isoform b precursor
- describe MASP-2 protein
- describe inositol 1,4,5-triphosphate receptor, type 2, isoform CRA_b
- describe unnamed protein product (GI 47077082)
- describe alpha-1-acid glycoprotein 1 precursor
- describe zinc-alpha-2-glycoprotein precursor (ZAG)
- describe HSCARG protein, isoform CRA_b
- describe alpha2-HS glycoprotein
- describe SNC66 protein
- define increased biomarkers
- describe methods for diagnosing prostate cancer
- define subject and post-prostate cancer treatment subject
- describe sample and determining a level of a biomarker

### Mass Spectrometry

- introduce mass spectrometry methods
- describe MALDI/TOF and SELDI/TOF techniques
- discuss limitations of MALDI
- describe laser desorption time-of-flight mass spectrometer
- explain algorithm for determining biomarker levels
- mention software programs for analyzing mass spectra

### Immunoassays

- introduce radioimmunoassay
- describe immunoradiometric assay
- explain enzyme-linked immunosorbent assay (ELISA)
- discuss sandwich ELISA and competitive ELISA
- introduce immunohistochemistry assay
- mention Western blotting technique

### RNA Detection Techniques

- introduce Northern blotting
- describe reverse transcription polymerase chain reaction (RT-PCR)
- explain symmetric gap ligase chain reaction (RT-AGLCR)
- introduce NASBA or 3SR technique
- describe Q-beta amplification
- explain strand displacement amplification
- introduce target mediated amplification
- mention in situ hybridization visualization

### Materials and Methods

- collect and process urine samples
- perform iTRAQ LC/LC/MS/MS analysis
- conduct immunoblot analyses
- perform pathways and interactive network systems biology analysis
- conduct statistical analysis
- describe chemicals used
- detail immunoblot analyses protocol
- outline LC/LC/MS/MS identification of differentially expressed proteins
- describe protein concentration determination
- detail protein digestion and peptide identification

### Results

- identify differentially expressed proteins using iTRAQ
- perform functional enrichment analysis
- identify differentially expressed pathways
- validate differentially expressed proteins using immunoblot analysis
- perform univariate analysis
- perform multivariate logistic regression modeling

### Discussion

- discuss the need for new markers to differentiate BPH from PCa
- discuss the potential of urinary biomarkers for noninvasive detection of PCa
- summarize the findings and implications of the study

